



The Advances of Cold Plasma in the Biomedicines

Guest Editor:

Message from the Guest Editor

Prof. Dr. Gyoocheon Kim

Department of Oral Anatomy,
School of Dentistry, Pusan
National University, Yangsan
50612, Korea

Deadline for manuscript
submissions:

closed (15 March 2022)

Plasma medicine, which started when cold plasma was applied to bacteria and cells, has made much progress for nearly 20 years. The scope of plasma research is expanding from just killing pathogens and cancer cells to tissue regeneration and selective cancer cell death. Among the numerous constituents of plasma, studies on which ones have medical functions and the mechanisms by which plasma-induced biomedical phenomena depend on are being actively conducted. Plasma medical devices are being developed based on these studies, and it is expected that various plasma medical devices will be introduced to the medical market in the near future.

In the current research climate, this Special Issue calls for advanced plasma medicine research results by explaining not only various life phenomena induced by plasma, but also cellular or histologic mechanisms. The scope of the research subject is limited to bacteria living in animals, animal cells and tissues, and biomaterials that can be inserted into the human body. Experimental as well as review papers consistent with this research topic are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)